

Cimduo[™] (lamivudine/tenofovir disoproxil fumarate) – New drug approval

- On March 2, 2018, Mylan announced the FDA approval of Cimduo (lamivudine/tenofovir disoproxil fumarate), to be used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg.
- Lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) are both nucleo(t)side reverse transcriptase inhibitors, and are available as individual products approved for the treatment of HIV-1 infection in combination with other anti-retroviral agents.
- The approval of Cimduo was based on data from a double-blind, active-controlled multicenter clinical trial comparing efavirenz [EFV] 600 mg + 3TC 300 mg + TDF 300 mg vs. EFV 600 mg + 3TC 300 mg + stavudine (d4T) 40 mg in 600 antiretroviral-naïve adult patients with HIV-1 infection.
 - Seventy-nine percent of patients were responders (HIV-1 RNA < 400 copies/mL) in the EFV/3TC/TDF group vs. 82% in the EFV/3TC/d4T group at week 48, and 68% of patients were responders in the EFV/3TC/TDF group vs. 62% in the EFV/3TC/d4T group at week 144.
 - Through 144 weeks of therapy, 62% and 58% of patients in the TDF and d4T groups, respectively, achieved and maintained confirmed HIV-1 RNA < 50 copies/mL.
- Cimduo carries a boxed warning for post-treatment acute exacerbations of hepatitis B.
- Other warnings and precautions include lactic acidosis and severe hepatomegaly with steatosis, new onset or worsening renal impairment, risk of hepatic decompensation when used with interferon- and ribavirin-based regimens, pancreatitis, bone effects, immune reconstitution syndrome, fat redistribution, and early virologic failure.
- The most common adverse reactions (> 10%) with Cimduo use were headache, pain, depression, diarrhea, and rash.
- The recommended dose of Cimduo is one tablet taken orally once daily with or without food.
 - Prior to initiation of Cimduo, patients should be tested for hepatitis B virus infection.
 - Serum creatinine, serum phosphorous, estimated creatinine clearance (CrCL), urine glucose, and urine protein should be assessed before initiating Cimduo and during therapy in all patients as clinically appropriate.
 - Use is not recommended in patients with CrCL less than 50 mL/min or patients with endstage renal disease requiring hemodialysis.
- Mylan plans to launch Cimduo in the second quarter of 2018. Cimduo will be available in a fixeddose combination tablet containing 300 mg 3TC and 300 mg TDF (equivalent to 245 mg of tenofovir disoproxil).



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.